Minnesota HF4349 modifies hospital reimbursement for biological products used in cell and gene therapy for rare diseases.

Minnesota HF4349 amends the state's health care statutes to adjust how hospitals are reimbursed for biological products used in cell and gene therapy for rare diseases. Effective July 1, 2025, the commissioner can provide separate reimbursement to hospitals for these products if the drug manufacturer agrees to a value-based arrangement. The reimbursement rate is based on the methodology used for outpatient drugs, and hospitals must be paid the actual acquisition cost for these biological products.

Minnesota HF4349 modifies hospital reimbursement for biological products used in cell and gene therapy for rare diseases.

Minnesota HF4349 amends the state's health care statutes to adjust how hospitals are reimbursed for biological products used in cell and gene therapy for rare diseases. Effective July 1, 2025, the commissioner can provide separate reimbursement to hospitals for these products if the drug manufacturer agrees to a value-based arrangement. The reimbursement rate is based on the methodology used for outpatient drugs, and hospitals must be paid the actual acquisition cost for these biological products.